These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Monoamine oxidase inhibition and CNS immunodeficiency infection. Koutsilieri E; Scheller C; ter Meulen V; Riederer P Neurotoxicology; 2004 Jan; 25(1-2):267-70. PubMed ID: 14697901 [TBL] [Abstract][Full Text] [Related]
67. Treatment-resistant depression: response to low-dose transdermal but not oral selegiline. Morgan PT J Clin Psychopharmacol; 2007 Jun; 27(3):313-4. PubMed ID: 17502787 [No Abstract] [Full Text] [Related]
68. Mao-B inhibitor know-how: back to the pharm. Burke WJ Neurology; 2009 Dec; 73(23):2048; author reply 2048. PubMed ID: 19996086 [No Abstract] [Full Text] [Related]
69. Placebo response in Parkinson trials using patient diaries: sites do matter. Ondo WG Clin Neuropharmacol; 2007; 30(5):301-4. PubMed ID: 17909309 [No Abstract] [Full Text] [Related]
70. Rasagiline (Azilect) for Parkinson's disease. Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358 [No Abstract] [Full Text] [Related]
71. Rasagiline -- is there a place for this drug in managing Parkinson's disease? Sharma JC Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281 [No Abstract] [Full Text] [Related]
72. Fluoxetine and selegiline--lack of significant interaction. Waters CH Can J Neurol Sci; 1994 Aug; 21(3):259-61. PubMed ID: 8000982 [TBL] [Abstract][Full Text] [Related]
73. [Pathogenesis and therapy of manganese poisoning (review)]. Mikhaĭlov VA Gig Tr Prof Zabol; 1971 Jun; 15(6):14-9. PubMed ID: 5001248 [No Abstract] [Full Text] [Related]
74. [The early therapy challenge]. Reichmann H Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310 [No Abstract] [Full Text] [Related]
75. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Naoi M; Maruyama W Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610 [TBL] [Abstract][Full Text] [Related]
76. [Jumex in the treatment of Alzheimer's disease]. Zarajczyk M Neurol Neurochir Pol; 1999; 33 Suppl 1():73-5. PubMed ID: 10404523 [No Abstract] [Full Text] [Related]
77. [Primary prevention with enhancer substances for a longer and healthier life]. Miklya I Neuropsychopharmacol Hung; 2013 Jun; 15(2):58-9. PubMed ID: 23817356 [No Abstract] [Full Text] [Related]
78. Psychopharmacology column: why choose selegiline transdermal system for refractory depression? Tobin M Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170 [No Abstract] [Full Text] [Related]
80. The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect Li XY; Jiao FY; Yao RX; Ju ZZ; Chen MJ; Ge JJ; Li G; Sun YM; Wu P; Wu JJ; Yen TC; Zuo C; Wang J; Lu JY; Liu FT; Mov Disord; 2023 Apr; 38(4):705-707. PubMed ID: 36707403 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]